Talking to Your Pharmacist Can Help Cut Down Your Meds

Deprescribing of inappropriate medications to seniors is more effective if pharmacists work with doctors and patients are educated about potentially harmful medications they are taking. Deprescribing is reducing the dose of or eliminating a medication that is no long necessary or may cause harm.

About 29% of Medicare beneficiaries aged 65 and older have filled a prescription that is on the Beers Criteria, a list of drugs compiled by the American Geriatrics Society that seniors should avoid because their risks outweigh their benefits. Examples include certain antihistamines, benzodiazepines (Ativan, Xanax) and sleep medications (Ambien, Lunesta).

About 500 seniors in Canada took part in a study along with their pharmacists. In order to be included in the trial, a participant needed to have taken one of the following Beers Criteria medications for at least three months: benzodiazepines (sedative medications) or prescription sleep drugs; first-generation antihistamines; Glynase (glyburide), a diabetes drug, and certain non-steroidal anti-inflammatory drugs (NSAIDs) that are used as pain relievers.

The seniors were divided into two groups. One group received a brochure about why a medication they were taking might be appropriate and some alternative options. Pharmacists in that group also received fillable PDF forms that they could send to a patient’s doctor suggesting that a medication was inappropriate and should be deprescribed. The other seniors and pharmacists did not receive any educational materials or other type of intervention.

After six months, 43% of seniors in the intervention group stopped filling a prescription for an inappropriate drug compared to 12% in the control group, according to results published in JAMA. The greatest difference was found in those who were taking a sedative or sleep drug. About 43% of seniors who received educational materials and pharmacist intervention stopped using those medications compared to just 9% of the other group.

“Interventions that engage patients, physicians, and pharmacists in the deprescribing process may be more effective than interventions that do not,” Michael A. Steinman, MD, and C. Seth Landefeld, MD, of, respectively, University of California San Francisco and University of Alabama at Birmingham, wrote in an accompanying editorial. “Given the inertia that accompanies long-term medication use, it is often insufficient to motivate only one of these groups to make a change.”


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Vitamin E, the Source of Mystery Vaping Illness

Vitamin E, the Source of Mystery Vaping Illness

A “breakthrough” in the investigation of vaping illness and death, EVALI, has been announced by Federal health officials and the CDC (Centers for Disease Control).

Heart and Thyroid Drugs, Juul

Heart and Thyroid Drugs, Juul

Some heart drugs can cause suicide risks, Juul shipped a million contaminated pods and hormone replacement therapy during pregnancy doesn’t cause language delays in the children.

  • Advertisement